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Highlights of the study 
- Clinical relapses were documented in 36 % of patients between 0-12 months 
- Corticosteroid-treated relapses occurred in 30 % of patients between 0-12 months 
- High disease activity and EDSS ≥ 5.5 before natalizumab predicted reactivation 
- Subsequent treatments failed to prevent reactivation 
- Washout time > 3 months was associated with an increased reactivation risk 
Abstract 
Background 
Natalizumab (NTZ) is widely used for highly active relapsing-remitting multiple sclerosis 
(MS). Inflammatory disease activity often returns after NTZ treatment discontinuation. We 
aimed to identify predictive factors for such reactivation in a real-life setting. 
Methods 
We conducted a retrospective survey in four Finnish hospitals. A computer-based search was 
used to identify all patients who had received NTZ for multiple sclerosis. Patients were 
included if they had received at least six NTZ infusions, had discontinued treatment for at 
least three months, and follow-up data was available for at least 12 months after 
discontinuation. Altogether 89 patients were analyzed with Cox regression model to identify 
risk factors for reactivation, defined as having a corticosteroid-treated relapse. 
Results 
At 6 and 12 months after discontinuation of NTZ, a relapse was documented in 27.0 % and 
35.6 % of patients, whereas corticosteroid-treated relapses were documented in 20.2 % and 
30.3 % of patients, respectively. A higher number of relapses during the year prior to the 
introduction of NTZ was associated with a significantly higher risk for reactivation at 6 
months (Hazard Ratio [HR] 1.65, p<0.001) and at 12 months (HR 1.53, p<0.001). Expanded 
NTZ = natalizumab, MS = multiple sclerosis, HR = hazard ratio, EDSS = Expanded Disability Status 
Scale, DMD = disease-modifying drug, RRMS = relapsing-remitting multiple sclerosis, VCAM-1 = 
vascular-cell adhesion molecule 1, CNS = central nervous system, PML = progressive multifocal 
leukoencephalopathy, SPMS = secondary-progressive multiple sclerosis, MRI = magnetic resonance 
imaging, CI = confidence interval, SD = standard deviation 
Disability Status Scale (EDSS) of 5.5 or higher before NTZ initiation was associated with a 
higher reactivation risk at 6 months (HR 3.70, p=0.020). Subsequent disease-modifying drugs 
(DMDs) failed to prevent reactivation of MS in this cohort. However, when subsequent 
DMDs were used, a washout time longer than 3 months was associated with a higher 
reactivation risk at 6 months regardless of whether patients were switched to first-line (HR 
7.69, p=0.019) or second-line therapies (HR 3.94, p=0.035). Gender, age, time since 
diagnosis, and the number of NTZ infusions were not associated with an increased risk for 
reactivation. 
Conclusion 
High disease activity and a high level of disability prior to NTZ treatment seem to predict 
disease reactivation after treatment cessation. When switching to subsequent DMDs, the 
washout time should not exceed 3 months. However, subsequent DMDs failed to prevent the 
reactivation of MS in this cohort. 
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1. Introduction 
Natalizumab (NTZ) is a humanized monoclonal antibody used in the treatment of relapsing-
remitting multiple sclerosis (RRMS)(Clerico et al., 2017). It is administered intravenously in 
every four weeks. NTZ has been proven effective in reducing the recurrence of relapses in 
multiple sclerosis (MS), and it is generally used in patients with a highly active course of 
disease or a poor response to the first-line therapies of MS(Kappos et al., 2011; Tramacere et 
al., 2015). By binding to the 4 subunit on 41 integrin, NTZ blocks the binding of these 
integrins to the vascular-cell adhesion molecule 1 (VCAM-1), which is expressed on the 
endothelial cells of blood vessels in the central nervous system (CNS)(Léger et al., 1997; 
Yednock et al., 1992). As a result, the migration of T-lymphocytes from the circulation to the 
CNS is prevented. The therapeutic effect of NTZ is mostly explained by this regulation of T-
lymphocyte adhesion and migration across the blood-brain barrier, but other α4-mediated 
effects of NTZ have also been suggested(Rice et al., 2005). 
The use of NTZ is limited due to the risk of progressive multifocal leukoencephalopathy 
(PML)(Tan and Koralnik, 2010). The risk of PML is increased in patients with long treatment 
periods, prior immunosuppressive treatment, and positive status with respect to anti-JC virus 
antibodies(Bloomgren et al., 2012). If the risk is considered too high, switching to an 
alternative disease-modifying drug (DMD) should be considered. 
In Finland, national treatment guidelines are followed when selecting DMDs for MS(Multiple 
Sclerosis: Current Care Guidelines, 2019). In the Finnish national guidelines, NTZ is 
positioned either as a first-line or second-line therapy for highly active RRMS with no anti-
JC virus antibodies. Cessation of treatment is advised if seroconversion occurs. NTZ is 
officially licensed only for RRMS in Finland, but it is sometimes used in secondary-
 
progressive multiple sclerosis (SPMS) patients who experience clinical relapses(Multiple 
Sclerosis: Current Care Guidelines, 2019). 
NTZ is cleared from circulation in approximately two months after discontinuation of 
treatment, but some residual effects may persist for up to 6 months(O’Connor et al., 2011; 
Stüve et al., 2006). As expected, reactivation of MS has been shown to occur during the first 
year after discontinuation of NTZ in some patients(Fox et al., 2014; Gueguen et al., 2014; 
Havla et al., 2011; Iaffaldano et al., 2015; Kerbrat et al., 2011; Lo Re et al., 2015; O’Connor 
et al., 2011; Salhofer-Polanyi et al., 2014; West and Cree, 2010). A recent systematic review 
and meta-analysis of six studies demonstrated that younger age, higher number of relapses 
and gadolinium-enhancing lesions before initiation of treatment as well as fewer NTZ 
infusions were associated with an increased risk for disease reactivation after cessation of 
treatment(Prosperini et al., 2019).  
There are no established guidelines on how to treat MS patients discontinuing NTZ therapy, 
but recent reports have suggested that subsequent treatment with other DMDs should be 
initiated within 3 months after discontinuation in order to prevent disease 
reactivation(Iaffaldano et al., 2015; Jokubaitis et al., 2014; Kappos et al., 2015; Lo Re et al., 
2015; Salhofer-Polanyi et al., 2014). However, most of the current evidence comes from 
observatory studies with heterogeneous study settings, and only few randomized trials have 
been published(Fox et al., 2014; Kappos et al., 2015; O’Connor et al., 2011). Our purpose 
was to evaluate the predictive factors for post-NTZ disease reactivation in an unselected 
clinical cohort of MS patients in a real-life setting. 
 
 
 
 
2. Material and methods 
2.1 Study population 
This retrospective study was carried out using data from four Finnish hospitals covering a 
catchment area of 1.3 million residents. Three university hospitals (Kuopio University 
Hospital, Tampere University Hospital and Oulu University Hospital) from different parts of 
Finland and one medium-sized central hospital (Central Hospital of Mikkeli) were chosen to 
represent MS treatment in Finland. The study was approved by the Research Ethics 
Committee of the Northern Savo Hospital District, Kuopio, Finland, and had an institutional 
approval from each participating hospital.  
MS patients were identified by a computer-based search using the ICD-8, -9 or -10 diagnosis 
of MS and treatment with NTZ as search criteria. Patients were included in the study if they 
had received at least six consecutive infusions of NTZ before the treatment was discontinued 
and follow-up data was available for at least 12 months after the last infusion. A 
discontinuation was defined as a three-month period without any NTZ infusions. Shorter gaps 
between infusions were not considered relevant. We identified a total of 101 MS patients who 
had discontinued NTZ treatment in years 2009-2016, and 89 of them met the inclusion 
criteria. A flowchart displaying the selection of the study cohort is shown in Figure 1. 
 
2.2 Methods 
The patient records were systematically reviewed from the time of the first symptom to the 
latest available contact with the hospital. Data was collected from both paper archives and the 
hospital districts’ electronic patient information systems. The following variables were 
collected: gender; onset symptom of MS; time from diagnosis to the initiation of NTZ 
 
treatment; existence of gadolinium-enhancing lesions in the pre-NTZ magnetic resonance 
imaging (MRI) scan; number of NTZ infusions; adverse events during NTZ treatment; 
primary reason for the discontinuation of NTZ; prior and subsequent DMDs; washout time 
between DMDs; and all courses of corticosteroid treatment. Age was collected both at the 
time of diagnosis and at NTZ initiation. Expanded Disability Status Scale (EDSS) was 
collected at diagnosis, at NTZ initiation, and at NTZ discontinuation. The number of relapses 
during the year before NTZ initiation and the year after NTZ discontinuation were collected. 
In our analysis, the onset symptom of MS was also regarded as a relapse. Relapses were 
collected in two categories. First, all reported relapses were collected regardless of whether 
they required corticosteroid treatment or not. Second, only relapses which required 
corticosteroid treatment were collected. The latter were used to define reactivation in the 
statistical analysis. 
Reactivation was defined as having experienced at least one corticosteroid-treated relapse 
after NTZ discontinuation. Rebound was defined as an increase in the yearly number of all 
relapses after the discontinuation of NTZ treatment when compared to the year before the 
initiation of NTZ. Washout time was defined as the time between the last infusion of NTZ 
and the initiation of the following treatment. In the analysis, EDSS was categorized into two 
groups with a cut point of 5.5.  
 
2.3 Statistical analysis 
Univariate Cox regression model was first used to identify individual variables associated 
with the risk of reactivation at 6 and 12 months of follow-up. Variables with statistically 
significant associations in the univariate model were then re-analyzed with multivariate Cox 
regression. The effect of subsequent DMDs administered after the cessation of NTZ 
 
treatment was analyzed using univariate Cox regression with patient as a random effect, and 
subgroup analysis was performed to determine whether a washout of 0-3 months or longer 
than 3 months was associated with the risk of reactivation. Results of the Cox regression 
analyses are shown as hazard ratios (HR) with 95 % confidence intervals (CI). Statistical 
analysis for the risk of rebound was not performed, as there were only few cases representing 
possible rebound in the cohort. Data was expressed as means with standard deviations (SD) 
or frequencies with percentages. Statistical analysis was performed using SPSS Statistics 24.0 
and R version 3.5.1. Statistical significance was defined as two-tailed p < 0.05. 
 
  
 
3. Results  
 
3.1 Patient characteristics  
A total of 89 patients were included in the study. At the time of NTZ initiation, 95.5 % 
(n=85) had RRMS and 4.5 % (n=4) had SPMS. The patients received a mean number of 26.9 
(range 6-85, SD±15.7) infusions of NTZ. Clinical characteristics of the study cohort are 
shown in Table 1. 
Other DMDs were used before NTZ in 85.4 % (n=76) of the patients (Table 2). The most 
common preceding DMD immediately prior to the initiation of NTZ was glatiramer acetate 
(39.3 %, n=35). NTZ was used as a first-line therapy in 14.6% (n=13) patients. Of these 13 
treatment-naive patients, five had been observed without treatment for more than 12 months 
after the diagnosis of MS. For the rest of the treatment-naive patients (n=8), NTZ was 
initiated within 12 months after the first symptom.  
In the pre-NTZ MRI scan, 32.6 % of the patients (n=29) in the study cohort had gadolinium-
enhancing lesions, while 67.4 % (n=60) had no gadolinium-enhancing lesions.  
Altogether 15 patients (16.9 %) had EDSS of 5.5 or higher at the initiation of NTZ treatment, 
indicating a high level of disability before the initiation of NTZ. All of these patients had 
RRMS and eight of them had gadolinium-enhancing lesions at the pre-NTZ MRI scan. In 13 
of these patients, the primary reason for initiating NTZ was aggressive course of disease, a 
poor response to earlier DMDs, or both. For the final two patients, the reason for initiating 
NTZ was marked radiological activity without clinical relapses.  
NTZ was mostly well-tolerated. The following adverse events were reported during 
treatment: fatigue (7.9 %, n=7); skin symptoms (4.5 %, n=4); nausea (3.4 %, n=3); 
arrhythmia (3.4 %, n= 3); headache (2.2 %, n=2); and fever (1.1 %, n=1). However, only 
 
three patients (3.4 %) discontinued treatment primarily due to adverse events. Skin symptoms 
reported in the study cohort included two cases of urticaria, one case of unspecified 
dermatitis, and one case of exacerbation of pre-existing atopic dermatitis. Of these four cases, 
only the exacerbation of atopic dermatitis led to discontinuation of NTZ treatment. The other 
two adverse events leading to treatment discontinuation were fatigue and fever.  No cases of 
PML were reported in the study cohort. As expected, positive status with respect to anti-JC 
virus antibodies was by far the most common reason for discontinuing treatment (57.7 %, 
n=51). All reasons for treatment discontinuation are shown in Table 1. 
After discontinuation of NTZ, subsequent DMDs were initiated for 68.5 % (n=61) and 77.5 
% (n=69) of the patients by the time of 6 and 12 months, respectively. Altogether 21.3 % 
(n=19) of the patients continued without treatment through the first 12 months of follow-up. 
Table 3 demonstrates the distribution of patients according to the use of subsequent DMDs 
and the length of washout time. The most common subsequent treatment was fingolimod 
(52.8 %, n=47). Other subsequent DMDs included subcutaneous interferons (9.0 %, n=8), 
glatiramer acetate (8.9 %, n=8), dimethyl fumarate (4.5 %, n=4), and alemtuzumab (2.2 %, 
n=2). In addition to DMDs, nine patients (10.1 %) received preventive high-dose 
corticosteroids without a clinical relapse within three months after the discontinuation of 
NTZ. Five of these courses of corticosteroids were given during the first month after 
discontinuation. 
 
3.2 Reactivation of MS after discontinuation of NTZ 
During the first 6 and 12 months of follow-up after the discontinuation of NTZ, a relapse was 
documented in 27.0 % (n=24, Table 1) and 35.6 % (n=32) of the patients, respectively. By 
the time of 6 and 12 months, 20.2 % (n=18) and 30.3 % (n=27) of patients had experienced a 
 
relapse which required corticosteroid treatment, thus meeting our definition for reactivation. 
The proportions of patients experiencing corticosteroid-treated relapses according to the use 
of subsequent DMDs and the length of washout are demonstrated in Table 3. 
The results of the Cox regression analyses are shown in Table 4. A higher number of relapses 
during the year before NTZ initiation was associated with a significantly higher risk for 
reactivation at 6 months (HR 1.65, 95 % CI 1.26-2.15, p<0.001) and 12 months (HR 1.54, 95 
% CI 1.21-1.96, p<0.001) of follow-up. EDSS of 5.5 or higher at the time of NTZ initiation 
was associated with a significantly higher risk for reactivation at 6 months (HR 3.70, 95 % CI 
1.23-11.15, p=0.020) but not at 12 months of follow-up when compared to patients with less 
disability (EDSS 0-5.0). Conversely, EDSS of 5.5 or higher at the time of NTZ 
discontinuation was associated with a significantly higher risk for reactivation at 12 months 
(HR 2.63, 95 % CI 1.12-6.20, p=0.027) but not at 6 months of follow-up. 
According to the univariate analysis, the following variables were not associated with the risk 
of clinical reactivation after discontinuation of NTZ: gender; age at the initiation of NTZ 
treatment; time from diagnosis; number of NTZ infusions; and multifocal onset symptoms 
when compared to other forms of disease onset. These non-significant variables were not 
included in the multivariate model. 
Univariate Cox regression model with patient as a random effect was used to analyze the 
effect of subsequent DMDs after NTZ cessation on the risk of reactivation. In this analysis, 
the patients’ status with respect to DMDs was classified into three groups, which were 
compared with each other: first-line therapies (dimethyl fumarate, glatiramer acetate, and 
interferons); second-line therapies (alemtuzumab and fingolimod); and no DMDs. Subgroup 
analysis was done separately to compare patients with a washout time of 0-3 months to 
patients with a washout time longer than 3 months. According to the analysis, the use of 
 
subsequent DMDs was not significantly associated with the risk of reactivation at 6 or 12 
months of follow-up. The results were the same in the first-line and second-line therapy 
group. However, the subgroup analysis showed that patients switching to subsequent DMDs 
after a washout longer than 3 months were in fact at higher risk for reactivation (Table 4) 
when compared to patients without treatment. 
Altogether eight patients (9.0 %) showed clinical signs of rebound activity according to the 
number of relapses they experienced during the year after NTZ discontinuation. These 
patients experienced their first clinical relapse 1-4 months after discontinuation of NTZ with 
a median of 3 months. Data of all patients who experienced rebound are shown in Table 5. 
 
  
 
4. Discussion 
In our study, we demonstrated that 20.2 % of patients experienced clinical reactivation of MS 
within 6 months after discontinuation of NTZ. In previous studies, the proportion of patients 
experiencing relapses after NTZ discontinuation has ranged from 13.5 to 58 % (Jokubaitis et 
al., 2014; Sangalli et al., 2014; West and Cree, 2010). This variability reflects differences in 
study populations and the difficulty of defining what constitutes as a relapse. We avoided this 
problem by using only corticosteroid-treated relapses to define reactivation.  
We demonstrated that a high number of relapses during the year prior to NTZ initiation was 
significantly associated with an increased risk for reactivation. Our findings are in line with 
the majority of previous reports.(Jokubaitis et al., 2014; Lo Re et al., 2015; Papeix et al., 
2016). However, there is one retrospective study reporting an opposite finding where lower 
annual relapse rate was associated with an increased risk for reactivation (Salhofer-Polanyi et 
al., 2014).   
We also found that EDSS of 5.5 or higher at the initiation of NTZ was a risk factor for the 
reactivation of MS at 6 months, and EDSS of 5.5 or higher at the discontinuation of NTZ at 
12 months of follow-up. To our knowledge, there are no previous reports on marked 
disability being a risk factor for reactivation of MS after NTZ cessation. We find this to be of 
interest, since high EDSS is often associated with SPMS, in which peripheral inflammation 
has been considered to be minimal. In our cohort, none of the patients with EDSS of 5.5 or 
higher at the initiation of NTZ were defined as having SPMS. Since this is a retrospective 
study, it must be taken into consideration that this might be false and the group could 
represent SPMS patients with activity(Lublin, 2014). The pathogenesis of SPMS is still 
partially unknown, but it seems that there is compartmentalized smoldering inflammation in 
the CNS(Correale et al., 2017), which might activate under certain conditions. On the other 
 
hand, the patients in our cohort may have had high EDSS due to residual symptoms from 
previous severe relapses and therefore they were true RRMS patients despite the high EDSS.  
Controversial findings have been reported about the association between the number of NTZ 
infusions and the risk for reactivation, as some studies have reported higher reactivation rates 
in patients with shorter exposure to NTZ(Lo Re et al., 2015; Miravalle et al., 2011; Prosperini 
et al., 2019; Vellinga et al., 2008). In our analysis, we did not detect any correlation between 
the number of NTZ infusions and the risk for reactivation. Furthermore, there was no 
correlation between age and reactivation risk, which is in line with a majority of earlier 
studies(Jokubaitis et al., 2014; Lo Re et al., 2015; Salhofer-Polanyi et al., 2014). 
A previous study by Iaffaldano et al has demonstrated the superiority of fingolimod in 
comparison to interferon beta and glatiramer acetate in controlling post-NTZ disease 
reactivation.(Iaffaldano et al., 2015). However, in our study none of the treatment strategies 
used after NTZ were able to significantly control reactivation of MS. Furthermore, previous 
reports suggest that subsequent DMDs should be initiated as soon as possible after 
discontinuation of NTZ to prevent reactivation(Iaffaldano et al., 2015; Kappos et al., 2015). 
In the present study, a short washout time did not reduce reactivation, but a washout time 
longer than 3 months was significantly associated with an increased risk of reactivation. 
However, the number of patients switching to subsequent DMDs within 3 months after NTZ 
was very small in our study, which may explain why the selected treatment strategies did not 
reduce reactivation risk in the analysis. 
Some of the previous studies have also identified a so-called rebound phenomenon or 
rebound effect after discontinuation of NTZ (Gueguen et al., 2014; Kerbrat et al., 2011; Lo 
Re et al., 2015; Salhofer-Polanyi et al., 2014; Sangalli et al., 2014; Vellinga et al., 2008). 
However, literature lacks a precise definition of the rebound effect, and not all studies have 
 
confirmed its existence(O’Connor et al., 2011). We defined rebound as an increase in the 
number of yearly relapses after discontinuation of NTZ when compared to the year before 
NTZ initiation and discovered that 9 % of our patients had experienced rebound activity. This 
is somewhat lower than what has been reported in the majority of earlier reports(Gueguen et 
al., 2014; Kerbrat et al., 2011; Lo Re et al., 2015), but almost similar to what was reported in 
two earlier studies(Salhofer-Polanyi et al., 2014; Sangalli et al., 2014).  
The study has limitations that should be noted. Due to the retrospective setting, some data 
were missing. Although it is a common custom in Finland for patients using DMDs to attend 
regular follow-up visits with neurological examinations, EDSS was not always documented. 
Furthermore, a substantial part of MRI data was missing. Therefore, we could not use it in the 
regression analysis. When describing pre-NTZ MRI, we only reported whether gadolinium-
enhancing lesions were present, as the exact number of lesions was not reported for every 
patient. 
We find the strength of this study to be its coverage of a large catchment area, the inclusion 
of four hospitals from different parts of Finland, and the use of an unselected real-life case 
series. The existence of our national treatment guidelines makes our data uniform and well 
representative of the actual treatment that Finnish MS patients received in years 2009-2016. 
Due to our national treatment guidelines, the indications for using different DMDs for 
reducing disease activity and prescribing corticosteroids for relapses in MS are concordant 
between different study centers.  
Since approximately a fifth of MS patients discontinuing NTZ seem to suffer from 
reactivation regardless of the duration of their treatment, we suggest that NTZ should only be 
initiated with the purpose of using the treatment for long periods. None of the therapeutic 
strategies used in this cohort were able to control the return of disease activity. In the future, 
 
the efficacy of the more recently approved DMDs in preventing post-NTZ disease 
reactivation should be evaluated. Until then, close attention should be paid on patient 
selection, regarding fertile women with family plans in particular. Washout times should be 
kept as short as possible after NTZ cessation. 
 
 
5. Conclusions 
Discontinuation of NTZ treatment may lead to a marked reactivation of MS. High disease 
activity and a high level of disability prior to NTZ initiation seem to predict such reactivation, 
which could not be prevented with subsequent DMDs. A washout time longer than 3 months 
was a risk factor for post-NTZ disease reactivation. 
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Figure 1. The selection of the study cohort. NTZ = natalizumab. 
 
  
101 patients who had discontinued NTZ 
treatment between years 2009-2016
89 patients included in the analysis
13 treatment-naive patients
76 patients switched from other 
treatments
9 patients excluded for receiving < 6 
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months of follow-up
 
 
Table 1. Clinical characteristics of the study cohort (n=89). SD = standard deviation, NTZ = 
natalizumab, EDSS = Expanded Disability Status Scale, PML = progressive multifocal 
leukoencephalopathy. *Positive anti-JC virus antibodies, long treatment period and/or prior 
immunosuppressive treatment 
  
 Patients with at least 
one relapse at 6 
months after cessation 
(n=24) 
Patients with no 
relapses at 6 months 
after cessation 
(n=65) 
All patients 
(n=89) 
Female gender, n (%) 17 (70.8 %) 46 (70.8 %) 63 (70.8 %) 
Age at the time of diagnosis, years, range (mean ±SD) 17-50 (27.9 9.2) 15-55 (31.48.9) 15-55 (30.4 ±9.0)  
Age at NTZ initiation, years, range (mean ±SD)  21-63 (34.511.2) 20-56 (36.69.6) 20-63 (36.0 ±10.1) 
Time from diagnosis at NTZ initiation, years, range (mean ±SD) 0-21 (6.25.8) 0-25 (5.35.6) 0-25 (5.5 ±5.6) 
EDSS at the time of diagnosis, range (mean ±SD) 1.0-6.0 (2.61.6) 0-5.0 (2.01.3) 0-6.0 (2.2 ±1.4) 
EDSS at NTZ initiation, range (mean ±SD) 1.0-7.5 (4.01.8) 0-7.0 (3.41.8) 0-7.5 (3.6 ±1.8) 
Duration of NTZ treatment 
< 12 months, n (%) 
12-36 months, n (%) 
> 36 months, n (%) 
 
4 (16.7 %) 
15 (62.5 %) 
5 (20.8 %) 
 
9 (13.8 %) 
38 (58.5%) 
18 (27.7 %) 
 
13 (14.6 %) 
53 (59.6 %) 
23 (25.8 %) 
Primary reason for the cessation of NTZ treatment, 
Risk of PML considered too high*, n (%) 
Inefficacy of treatment, n (%) 
Pregnancy plans or pregnancy, n (%) 
Adverse events, n (%) 
Difficulties with peripheral venous cannulation, n (%)  
Patient’s own wish to discontinue treatment, n (%) 
 
11 (45.8 %) 
7 (29.2%) 
4 (16.7%) 
1 (4.2 %) 
1 (4.2%) 
0 (0 %) 
 
 
50 (76.9 %) 
9 (13.8%) 
3 (4.6%) 
2 (3.1 %) 
0 (0 %) 
1 (1.5 %) 
 
61 (68.5 %) 
16 (18.0 %) 
7 (7.9 %) 
3 (3.4 %) 
1 (1.1 %) 
1 (1.1 %) 
 
 
Table 2. The distribution of disease-modifying drugs used immediately prior to the initiation 
of natalizumab. 
 
n % 
Glatiramer acetate 35 39.3 
Subcutaneous interferons 28 31.5 
Mitoxantrone 8 9.0 
Azathioprine 4 4.5 
Fingolimod 1 1.1 
No disease-modifying drugs before natalizumab 13 14.6 
 
 
 
 
 
  
 
 
Table 3. The distribution of patients according to use of subsequent disease-modifying drugs 
(DMDs) and length of washout. The proportions of patients with corticosteroid-treated 
relapses at 6 and 12 months are presented within each group. 
 
 No. of patients 
in group 
Corticosteroid-treated relapse 
at 0-6 months, n (%) 
Corticosteroid-treated relapse 
at 0-12 months, n (%) 
No subsequent DMDs 
 
20 4 (20.0 %) 8 (40.0 %) 
DMD initiated after 0-3 
months of washout 
13 1 (7.7 %) 4 (30.8 %) 
DMD initiated after >3 
months of washout 
56 13 (23.2 %) 15 (26.8 %) 
 
All patients 
 
89 18 (20.2 %) 27 (30.3 %) 
 
  
 
 
Table 4. The results of the statistical analysis. Hazard rations (HR) and 95 % confidential 
intervals (95 % CI) are displayed for the statistically significant findings. For clarity, results 
with p>0.05 have been removed. NTZ = natalizumab, EDSS = Expanded Disability Status 
Scale, DMD = disease-modifying drug. *p<0.05, **p<0.01, ***p<0.001. 
 
 6 months 
HR (95 % CI) 
12 months 
HR (95 % CI) 
Univariate analysis   
 No. of relapses during the year before initiation of NTZ 1.71 (1.29-2.27)*** 1.66 (1.29-2.14)*** 
 EDSS 5.5 or higher at the initiation of NTZ 2.84 (1.05-7.69)* - 
 
EDSS 5.5 or higher at the discontinuation of NTZ 3.64 (1.38-9.57)** 2.94 (1.28-6.72)* 
 Gender - - 
 Age at the initiation of NTZ - - 
 Time from diagnosis - - 
 Number of NTZ infusions - - 
 Multifocal onset symptoms - - 
    
Multivariate analysis   
 No. of relapses during the year before initiation of NTZ 1.65 (1.26-2.15)*** 1.54 (1.21-1.96)*** 
 EDSS 5.5 or higher at the initiation of NTZ 3.7 (1.23-11.15)* - 
 EDSS 5.5 or higher at the discontinuation of NTZ - 2.63 (1.12-6.20)* 
    
The effect of subsequent DMDs  
(univariate Cox regression with patient as a random effect) 
  
 First-line DMD 0-3 months of washout - - 
 First-line DMD >3 months of washout 7.69 (1.40-42.19)* - 
 Second-line DMD 0-3 months of washout - - 
 Second-line DMD >3 months of washout 3.94 (1.11-14.08)* - 
 
  
 
 
 
Table 5. Descriptive data of all eight patients who had experienced rebound. DMD = disease-
modifying drug, NTZ = natalizumab, EDSS = Expanded Disability Status Scale 
Patient No. of 
previous 
DMDs 
No. of NTZ 
infusions before 
discontinuation 
No. of relapses 
during the year 
before NTZ 
No. of relapses 
during the year 
after NTZ 
EDSS at 
initiation of 
NTZ 
EDSS at 
discontinuation 
of NTZ 
1 2 6 2 3 4.0 4.0 
2 2 33 2 3 2.0 1.5 
3 3 38 5 7 2.0 2.0 
4 2 11 2 3 6.0 6.5  
5 2 12 2 3 4.0 4.0 
6 3 41 0 2 3.0 4.0 
7 2 12 1 3 6.5 7.0 
8 2 6 2 3 6.0 6.5 
 
 
 
 
